CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohn's Disease patients with open fistulas

被引：0
|
作者：
Schreiber, S. [1 ]
Lawranc, I [2 ]
Thomsen, O. [3 ]
Hanauer, S. [4 ]
Bloomfield, R. [5 ]
Sandborn, W. [6 ]
机构：
[1] Univ Kiel, Hosp Gen Internal Med, Kiel, Germany
[2] Univ Western Australia, Fremantle Hosp, Fremantle, WA, Australia
[3] Univ Copenhagen, Herlev Hosp, DK-2730 Herlev, Denmark
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] UCB Pharma, Slough, Berks, England
[6] Mayo Clin, Rochester, MN USA
来源：
INFLAMMATORY BOWEL DISEASES | 2008年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [31] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE REFRACTORY TO INFLIXIMAB AND ADALIMUMAB
    Jose, Morales Lara Ma
    Penella Monica, Martinez
    Guzman Diana, Lacruz
    Vidal Vanessa, Jorge
    Maneiro Vicente, Santaclara
    Sanchez Senador, Moran
    del Carmen, Mira Sirvent Ma
    ATENCION FARMACEUTICA, 2009, 11 (03): : 178 - 180
  • [32] Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn's Disease? A Meta-analysis of Controlled Clinical Trials
    Nikfar, Shekoufeh
    Ehteshami-Afshar, Solmaz
    Abdollahi, Mohammad
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2013, 15 (08) : 668 - 675
  • [33] Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease
    Mocciaro, Filippo
    Orlando, Ambrogio
    Renna, Sara
    Rizzuto, Maria Rosa
    Cottone, Mario
    JOURNAL OF CROHNS & COLITIS, 2011, 5 (02): : 173 - 174
  • [34] Serum Certolizumab Pegol Levels and Antibodies to Certolizumab Pegol Are Associated With C-Reactive Protein Levels in Patients With Crohn's Disease
    Yarur, Andres
    Hauenstein, Scott
    Czul, Frank
    Lockton, Steven
    Quintero, Maria
    Barkin, Jamie
    Jain, Anjali
    Singh, Sharat
    Abreu, Maria
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S523 - S523
  • [35] Safety Profile of Extraintestinal Manifestations of Crohn's Disease During Treatment With Certolizumab Pegol
    Randall, Charles W.
    Wolf, Douglas C.
    Spearman, Marshall
    Kosutic, Gordana
    Coarse, Jason
    Loftus, Edward V., Jr.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S780 - S781
  • [36] Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease
    Augustine, Jill M.
    Lee, Jeannie K.
    Armstrong, Edward P.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (05) : 599 - 609
  • [37] Does Obesity Impact Treatment Efficacy of Adalimumab and Certolizumab Pegol in Crohn's Disease?
    Click, Benjamin
    Tuskey, Anne G.
    Behm, Brian W.
    GASTROENTEROLOGY, 2012, 142 (05) : S361 - S361
  • [38] Adalimumab and Certolizumab Pegol for the Treatment of Crohn's Disease: Does BMI Make a Difference?
    Moore, John M.
    Beaulieu, Dawn B.
    Horst, Sara N.
    Armstrong, Sharelle
    Duncan, Pamela A.
    Wagnon, Julianne H.
    Duley, Caroline
    Ward, Jodie
    Rosenbury, Audra
    Schwartz, David A.
    GASTROENTEROLOGY, 2011, 140 (05) : S588 - S588
  • [39] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard N.
    Spehlmann, Martina E.
    Wolf, Douglas C.
    Lee, Scott
    Rutgeerts, Paul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695
  • [40] Mucosal Healing in Patients Receiving Certolizumab Pegol for Crohn's Disease (CHARTER Study)
    Randall, Charles
    Herrera, Christian
    Taboada, Carlo
    Fincke, Christopher
    Havranek, Russell
    Zurita, Franz
    Stump, David
    Gossen, Gary
    Vidaurri, Daniela
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S436 - S437
12345